Literature DB >> 10922456

Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa).

T S Bishiniotis1, S Antoniadou, G Katseas, D Mouratidou, A G Litos, N Balamoutsos.   

Abstract

We treated 19 women with malignant cardiac tamponade due to advanced breast cancer with subxiphoid pericardiocentesis and local thiotepa instillation. The method has no serious side effects, prevents pericardial fluid reaccumulation, and, combined with systemic adjuvant therapy, prolongs survival.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10922456     DOI： 10.1016/s0002-9149(00)00937-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

1.  [Differentiation of malignant from nonmalignant, inflammatory pericardial effusions with biomarkers].

Authors:  Konstantinos Karatolios; Peter Alter; Bernhard Maisch
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

2.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

Review 3.  The common and distinct target genes of the p53 family transcription factors.

Authors:  K Harms; S Nozell; X Chen
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

4.  Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis.

Authors:  Szymon Darocha; Michał Wilk; Anna Walaszkowska-Czyż; Jarosław Kępski; Rafał Mańczak; Marcin Kurzyna; Adam Torbicki; Sebastian Szmit
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

5.  Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.

Authors:  Mie Kotake; Hisao Imai; Kyoichi Kaira; Tomomi Fujisawa; Yasuhiro Yanagita; Koichi Minato
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-27       Impact factor: 3.333

Review 6.  Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.

Authors:  Lisa M Tilemann; Markus B Heckmann; Hugo A Katus; Lorenz H Lehmann; Oliver J Müller
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.